Generic Falcigo, Artesunate
|
Malaria is a grave health as well as economic crisis, particularly in the region of Africa to the south of the Sahara Desert. In reply to the mounting demand for novel treatments, healthcare providers from all over the world have applied anti-malarial drugs like Falcigo (Artesunate) in conjunction with others. The outcomes of these combination therapies have been showing potential.
About the Drug
Artesunate under the brand name Falcigo is an antimalarial medication. It is soluble in water and a hemisuccinate derived from dihydroartemisinin. Artemisinin is a sesquiterpene lactone separated from Artemisia annua (wormwood of southeastern Europe to Iran), an herbaceous plant that has habitually been utilized in China for the intervention of malaria. Artesunate along with its dynamic metabolite dihydroartemisinin is effective blood schizonticides that work actively against the ring stage of the parasite.
Artesunate is a perfect treatment option for life-threatening malaria, including cerebral or brain malaria. It is also combat-ready against chloroquine (an antimalarial medication applied to care for malaria and amebic infection of the intestines and general lupus erythematosus) and mefloquine (an antimalarial drug that is effectual in instances that do not react to chloroquine) resistant strains of P. falciparum.
Drug Composition
Falcigo is supplied in both tablet and injection form. Each tablet contains 50 mg of Artesunate which is the active ingredient in this medicinal drug. On the other hand, each vial for injection comprises 60 mg of sterile Artesunate. The injection pack also contains 1ml ampoule of sodium bicarbonate BP (5%) and 5ml ampoule of sodium chloride IP (0.9%).
Indications
Falcigo (Artesunate) tablets are indicated for the treatment of uncomplicated falciparum malaria in cases where there is proof of chloroquine, pyrimethamine/sulfadoxine, mefloquine and quinine (a sour alkaloid obtained from chinchona bark and employed in malaria treatment) resistance.
Drug Effects
Pharmacokinetic information regarding Falcigo in human beings is meager, with no facts presenting the range or level of absorption or the systemic circulation of the medication. After being administered by means other than through the alimentary tract (as by means of muscles or a vein injection), Artesunate is undergone hydrolysis quickly to form the active metabolite dihydroartemisinin. The oral composition is possibly hydrolyzed in entirety before getting into the systemic distribution. The highest serum levels take place inside one hour of an oral dosage of Artesunate and continue up to 4 hours. Subsequent to the administration by means of a vein, elimination half-life of 45 minutes has been testified. Dihydroartemisinin boasts a plasma elimination half-life of below 2 hours, which may retard the growth of resistance to Falcigo (Artesunate).
Dosage & Administration
In case of uncomplicated malaria, Falcigo as monotherapy is applied in those cases where the application of artemisinin combinations is unimaginable, for instance owing to patient intolerance to mefloquine. Monotherapy with artemisinin medications may be practiced in courses of therapy of 7 days with every attempt being made to check conformation. Administering the medicine in shorter regimes to non-immune persons results in intolerably high degrees of outbreak. The normal dosing plan is 4 mg per kilogram loading dose on the first day and 2 mg per kilogram one time a day for 6 days thereafter.
In combination therapy, the standard dosing plan of Falcigo is 4 mg per kilogram on one occasion a day for 3 days plus mefloquine (15 mg or 25 mg of base per kilogram) as a solitary dosage or split dosage on the second and/or third day.
